Clinical Research Directory
Browse clinical research sites, groups, and studies.
LTG-321 - Itraconazole Drug-drug Interaction (DDI) Study
Sponsor: Latigo Biotherapeutics
Summary
This Phase 1, single-center, open-label, randomized, parallel-group study will evaluate the effect of itraconazole on the PK of LTG-321 and its metabolite(s), and the safety and tolerability of LTG-321 administered alone and in combination with itraconazole, in healthy participants.
Official title: A Phase 1, Open-Label Study to Evaluate the Effect of Strong CYP3A Inhibition on the Pharmacokinetics of LTG-321 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2026-12-04
Completion Date
2026-12-30
Last Updated
2026-11-04
Healthy Volunteers
Yes
Conditions
Interventions
LTG-321
LTG-321 is a novel, orally bioavailable, small molecule NaV1.8 inhibitor being developed as a non-opioid analgesic product
Itraconazole (200 mg)
Itraconazole is a known strong CYP3A inhibitor